People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

For decades, fast-food has been America’s common denominator. No matter if you were rich or poor or somewhere in the middle, you could always count on a quick, cheap meal at a burger joint, ...

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary ...

It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...

And a review study published in Nutrients showed that yerba maté may help support energy levels, aid in weight loss by ...

For 2025, Waters expects constant currency sales growth of 4.5%-7%, translating to total reported sales growth of approximately 2.5%-5% due to FX headwinds. Non-GAAP EPS guidance is projected at ...

Known for his smooth, velvety voice, music icon Frank Sinatra was a great interpreter of the Great American Songbook. In “It Was a Very Good Year,” he outlines the times of his life at 17, 21, 35 and ...

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive growth. The number of Americans taking GLP-1s for weight loss rose more ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Those who lose weight on Ozempic often find success has left them with sagging skin—a common side effect that is driving a ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...